All In Biotech

Drug Trial Radar · NCT07203287

Risk of Acute Complications With Rocuronium vs Cisatracurium in Patients With Chronic Kidney Disease

Last checked: Nov 20, 2026Latest source record: Oct 20, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingRandomized with 490 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

490

Planned (sponsor's estimate)

Start

Aug 26, 2025

Primary completion

Dec 31, 2026

Study completion Aug 26, 2027

Sponsor

Lead sponsor
The University of Texas Medical Branch, GalvestonAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Oct 2, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Randomized
Model
Parallel
Masking
Single (outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 80 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

The purpose of the study is to determine which combination of neuromuscular blocking agent and reversal agent is safer to use during anesthesia for patients with chronic kidney disease. The main question it aims to answer is "The use of Cisatracurium with neostigmine leads to less post-operative pulmonary complications than Rocuronium with sugammadex."

Conditions

  • Post Operative Pulmonary Complications
  • Neuromuscular Blockade
  • General Anesthesia

Interventions

  • RocuroniumDrug

    Will be assessing neuromuscular blockade with rocuronium and reversal with sugammadex

  • CisatracuriumDrug

    Will be assessing neuromuscular blockade with neostigmine and reversal with neostigmine

  • SugammadexDrug

    Will be assessing neuromuscular blockade with rocuronium and reversal with sugammadex

  • NeostigmineDrug

    Will be assessing neuromuscular blockade with neostigmine and reversal with neostigmine

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Post Operative Pulmonary Complications (PPCs)Time frame: 7 days

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • University of Texas Medical Branch

    Galveston, Texas · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.